drugset / Trial / NCT01197573
Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
Completed
103 enrolled
The Cleveland Clinic
Health Resources and Services Administration (HRSA) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality, and may ultimately result in a greater number of transplantable livers and kidneys.
Timeline
- Start
- 2010-04
- Primary completion
- 2015-10
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alteplase | Protein / enzyme biologic | — | — |
Indications
No indication recorded.